Imara M&A

● ● ● Significant Need Remains for More Treatment Options for CML Challenges with Current Standard of Care Approximately 1 in 5 patients switch therapy within the first year and ~40% of patients switch in the first 5 years (1L & 2L) Growing 3L+ patient population (>25% of CP-CML) with limited treatment options Except for asciminib, the approved TKIs have poor kinase selectivity resulting in tolerability issues that impact efficacy Comorbidities, restrictions with concomitant medications, and specific administration requirements impede long-term patient adherence • Fewer than 10% of patients successfully achieve sustained treatment-free remission (TFR) Majority of HCPs (77%) indicated need for more effective, safe, and tolerable agents in CML Switching Dynamics Demonstrate Unmet Need Rationale for Treatment Switching Intolerance ~30% Other ~5% Lack of response ~30% Loss of response (eg, >2 years post-initiation) ~35% In the US and EU3, majority of treatment switches across lines of therapy and TKIs are driven by intolerance or initial lack of molecular response (~60% combined) TKI = Tyrosine kinase inhibitors, HCP= Healthcare professional References: HCP Qualitative & Quantitative Interviews (ClearView); Hochhaus A et al. ASH 2015; Hochhaus A et al. Leukemia. 2017; 31(7):1525-1531; Osorio S et al. Ann Hematol. 2018; 97(11):2089-2098; Rea et al. Blood. 2021; blood.2020009984; Baccarani M and Gale RP. Leukemia. 2021; 35:2199-2204; Icsluig® (ponatinib) USPI; Sprycel® (dasatinib) USPI; Tasigna® (nilotinib) USPI.; Bosulife (bosutinib) USPI 20

View entire presentation